Compliance Status
Halal
Screened on Oct 18, 2026 · AAOIFI Standard 21
Good
Is Alnylam Pharmaceuticals, Inc. (ALNY) halal? Halal. Based on AAOIFI screening, Alnylam Pharmaceuticals, Inc. passes both qualitative (business activity) and quantitative (financial ratio) screens with a compliance score of 76/100 (Grade: B+).
Quote this verdict
HalalScreener rates Alnylam Pharmaceuticals, Inc. (ALNY) Halal, 76/100, grade B+ under AAOIFI Standard 21, screened Oct 18, 2026. Source: https://halalscreener.app/en/stock/ALNY
Business activity
What the company sells is permissible.
Company debt
Well clear of the limitHow much the company borrows, compared to its total value. AAOIFI allows up to 30%.
The verdict above is final and free.
Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.
Screened according to AAOIFI Standard 21
What this means for you
You can own ALNY
It passes both the business activity and financial ratio screens under AAOIFI Standard 21.
Purification amount is Pro
We have screened ALNY's prohibited income, but the exact share you would need to purify is part of Pro.
ALNY: Is Alnylam Pharmaceuticals, Inc. Halal?
Alnylam Pharmaceuticals, Inc.
$231.83
Market Cap: 31.0B
Get an email if ALNY's halal status changes
We re-screen Alnylam Pharmaceuticals, Inc. daily. If the verdict moves, you hear about it the same day.
Free. One click sets it up, and you can unsubscribe any time.
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
Sector: Healthcare · Industry: Biotechnology
Shariah Compliance Status
Want to check the math yourself?
The verdict above is final and free. Pro members can verify every ratio behind it: interest-bearing deposits, prohibited income breakdown, and the full math.
AI Compliance Insight
PROInstitutional-grade Shariah analysis
See why ALNY is rated Halal with institutional-grade analysis
The verdict above is final and free.
Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.
Screened according to AAOIFI Standard 21
Compliance History
Halalnow
since Aug 2026
Not Halal
until the change above
Halal
until the change above
Tracked since Jun 2026. Updates automatically on each re-screen.
More Healthcare Stocks
Know the day ALNY's verdict changes
A free account keeps watch on 3 stocks and emails you when a verdict moves. You also get 3 questions for the AI Scholar. No card needed.
Frequently Asked Questions
Is Alnylam Pharmaceuticals, Inc. (ALNY) halal to invest in?
Why did Alnylam Pharmaceuticals, Inc. get a B+ compliance rating?
What could change Alnylam Pharmaceuticals, Inc.'s Shariah verdict?
How often is Alnylam Pharmaceuticals, Inc. re-screened for Shariah compliance?
Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.
Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.